SCHEMBL30344

SCHEMBL30344

O=Cc1csc(Br)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7499771 0.78 HDAC3 (0.36) —
SCHEMBL21008783 0.78 HDAC3 (0.57) —
SCHEMBL548197 0.75 — —
SCHEMBL1042072 0.73 — —
SCHEMBL1107430 0.73 — —
SCHEMBL2669007 0.73 — —
SCHEMBL5213645 0.73 — —
SCHEMBL8193502 0.73 — —
SCHEMBL2561104 0.72 HTR2B (0.46) —
Bromide SCHEMBL9367452 0.71 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
EP-4716532-A2 BICYCLIC HETEROARYL COMPOUNDS Quantx Biosciences US, Inc. (US) 2026-04-01 — — EP disclosed
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
EP-4667054-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY Novartis AG (CH) 2025-12-24 — — EP disclosed
US-12433895-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2025-10-07 — — US disclosed
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 — — US disclosed
WO-2025151517-A1 THIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS ASSOCIATED WITH MISSFOLDING OF ALPHA-SYNUCLEIN PROTEIN WAVEBREAK THERAPEUTICS LIMITED (US) 2025-07-17 — — WO disclosed
EP-3880660-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2025-07-02 — — EP disclosed
US-12338236-B2 Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders SUVEN LIFE SCIENCES LIMITED (IN) 2025-06-24 — — US disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 — — US disclosed
CN-1134438-C Bicyclic heteroaromatic compounds, preparation method and use thereof �ձ���ҩ��ʽ���� 2004-01-14 — — CN disclosed
US-20030176451-A1 Reacting a heterocyclic-methanesulfonyl substituted-quinazolineamine compound with amine compound LEO OSPREY LIMITED (GB) 2003-09-18 — — US disclosed
US-20020147205-A1 Heterocyclic compounds NOVARTIS AG (CH) 2002-10-10 — — US disclosed
CN-1292788-A Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors GLAXO GROUP LTD (GB) 2001-04-25 — — CN disclosed
EP-1047694-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-11-02 — — EP disclosed
WO-2000018770-A1 PYRROLOPYRROLONE DERIVATIVES AS ANTIVIRAL AGENTS GLAXO GROUP LIMITED (GB) 2000-04-06 — — WO disclosed
WO-1999035146-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-07-15 — — WO disclosed
US-5395845-A Insecticides ROUSSEL-UCLAF (FR) 1995-03-07 — — US disclosed
CN-1081675-A By the new pyrethroid of thiazolic alcohol derivative, its preparation method and as the purposes of agricultural chemicals ROUSSEL UCLAF (FR) 1994-02-09 — — CN disclosed
EP-0556123-A1 Pyrethrinoid esters of thiazolylalcohols, process for their preparation and their use as pesticides ROUSSEL UCLAF (FR) 1993-08-18 — — EP disclosed
Send feedback